NTRA vs. PFE: A Head-to-Head Stock Comparison

Updated on November 22, 2025

Here’s a clear look at NTRA and PFE, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	NTRA	PFE
Company Name	Natera, Inc.	Pfizer Inc.
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Pharmaceuticals
Market Capitalization	31.83 billion USD	145.01 billion USD
Exchange	NasdaqGS	NYSE
Listing Date	July 1, 2015	June 1, 1972
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of NTRA and PFE by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

NTRA vs. PFE: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	NTRA	PFE
5-Day Price Return	10.41%	2.75%
13-Week Price Return	39.27%	-0.32%
26-Week Price Return	47.16%	9.58%
52-Week Price Return	39.14%	-6.21%
Month-to-Date Return	13.38%	1.66%
Year-to-Date Return	42.48%	-5.54%
10-Day Avg. Volume	1.85M	126.04M
3-Month Avg. Volume	1.34M	58.66M
3-Month Volatility	34.17%	28.86%
Beta	1.56	0.43

Profitability

Return on Equity (TTM)

NTRA

-25.07%

Biotechnology Industry

Max: 96.19%
Q3: 12.45%
Median: -16.39%
Q1: -47.43%
Min: -131.19%

NTRA has a negative Return on Equity of -25.07%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

PFE

10.92%

Pharmaceuticals Industry

Max: 38.95%
Q3: 20.34%
Median: 11.59%
Q1: 3.32%
Min: -10.91%

PFE’s Return on Equity of 10.92% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.

NTRA vs. PFE: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

NTRA

-14.61%

Biotechnology Industry

Max: 84.13%
Q3: 19.34%
Median: -1.39%
Q1: -117.64%
Min: -296.77%

NTRA has a negative Net Profit Margin of -14.61%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

PFE

15.65%

Pharmaceuticals Industry

Max: 39.07%
Q3: 19.28%
Median: 13.48%
Q1: 5.73%
Min: -8.86%

PFE’s Net Profit Margin of 15.65% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

NTRA vs. PFE: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

NTRA

-16.62%

Biotechnology Industry

Max: 78.85%
Q3: 20.86%
Median: 0.51%
Q1: -128.29%
Min: -315.84%

NTRA has a negative Operating Profit Margin of -16.62%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

PFE

16.52%

Pharmaceuticals Industry

Max: 45.58%
Q3: 24.35%
Median: 18.05%
Q1: 7.58%
Min: -11.88%

PFE’s Operating Profit Margin of 16.52% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

NTRA vs. PFE: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	NTRA	PFE
Return on Equity (TTM)	-25.07%	10.92%
Return on Assets (TTM)	-17.74%	4.70%
Net Profit Margin (TTM)	-14.61%	15.65%
Operating Profit Margin (TTM)	-16.62%	16.52%
Gross Profit Margin (TTM)	63.66%	74.95%

Financial Strength

Current Ratio (MRQ)

NTRA

3.27

Biotechnology Industry

Max: 15.83
Q3: 7.97
Median: 4.06
Q1: 2.64
Min: 0.72

NTRA’s Current Ratio of 3.27 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

PFE

1.28

Pharmaceuticals Industry

Max: 5.45
Q3: 2.99
Median: 1.98
Q1: 1.29
Min: 0.78

PFE’s Current Ratio of 1.28 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

NTRA vs. PFE: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

NTRA

0.06

Biotechnology Industry

Max: 1.27
Q3: 0.62
Median: 0.13
Q1: 0.00
Min: 0.00

NTRA’s Debt-to-Equity Ratio of 0.06 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

PFE

0.67

Pharmaceuticals Industry

Max: 1.79
Q3: 0.78
Median: 0.31
Q1: 0.08
Min: 0.00

PFE’s Debt-to-Equity Ratio of 0.67 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NTRA vs. PFE: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

NTRA

-57.80

Biotechnology Industry

Max: 72.37
Q3: 1.71
Median: -15.18
Q1: -65.75
Min: -166.46

NTRA has a negative Interest Coverage Ratio of -57.80. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

PFE

7.89

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 10.15
Q1: 2.37
Min: -42.71

PFE’s Interest Coverage Ratio of 7.89 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

NTRA vs. PFE: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	NTRA	PFE
Current Ratio (MRQ)	3.27	1.28
Quick Ratio (MRQ)	3.01	0.97
Debt-to-Equity Ratio (MRQ)	0.06	0.67
Interest Coverage Ratio (TTM)	-57.80	7.89

Growth

Revenue Growth

NTRA vs. PFE: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

NTRA vs. PFE: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

NTRA

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

NTRA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

PFE

6.72%

Pharmaceuticals Industry

Max: 6.72%
Q3: 3.48%
Median: 1.90%
Q1: 0.00%
Min: 0.00%

With a Dividend Yield of 6.72%, PFE offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

NTRA vs. PFE: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

NTRA

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

NTRA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

PFE

98.75%

Pharmaceuticals Industry

Max: 199.58%
Q3: 85.87%
Median: 49.36%
Q1: 1.12%
Min: 0.00%

PFE’s Dividend Payout Ratio of 98.75% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

NTRA vs. PFE: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	NTRA	PFE
Dividend Yield (TTM)	0.00%	6.72%
Dividend Payout Ratio (TTM)	0.00%	98.75%

Valuation

Price-to-Earnings Ratio (TTM)

NTRA

Biotechnology Industry

Max: 115.91
Q3: 56.76
Median: 21.80
Q1: 15.79
Min: 4.51

P/E Ratio data for NTRA is currently unavailable.

PFE

14.69

Pharmaceuticals Industry

Max: 52.64
Q3: 29.89
Median: 20.77
Q1: 13.37
Min: 5.71

PFE’s P/E Ratio of 14.69 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

NTRA vs. PFE: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

NTRA

15.29

Biotechnology Industry

Max: 58.56
Q3: 29.31
Median: 8.30
Q1: 4.89
Min: 0.86

NTRA’s P/S Ratio of 15.29 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

PFE

2.30

Pharmaceuticals Industry

Max: 8.74
Q3: 4.66
Median: 2.37
Q1: 1.67
Min: 0.11

PFE’s P/S Ratio of 2.30 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

NTRA vs. PFE: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

NTRA

17.64

Biotechnology Industry

Max: 17.92
Q3: 10.38
Median: 4.78
Q1: 2.85
Min: 0.78

NTRA’s P/B Ratio of 17.64 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

PFE

1.46

Pharmaceuticals Industry

Max: 9.86
Q3: 5.28
Median: 2.48
Q1: 1.57
Min: 0.59

PFE’s P/B Ratio of 1.46 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

NTRA vs. PFE: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	NTRA	PFE
Price-to-Earnings Ratio (TTM)	--	14.69
Price-to-Sales Ratio (TTM)	15.29	2.30
Price-to-Book Ratio (MRQ)	17.64	1.46
Price-to-Free Cash Flow Ratio (TTM)	345.84	12.47